Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr. Reddy's
to release Q1 FY19 results on July 26, 2018 Earnings call slated for July 26, 6:30 PM IST / 9:00 AM EDT".
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code: RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) | Calvin Printer calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
Dr. Reddy's to release Q1
FY19 results on July 26, 2018
call slated for July 26, 6:30 PM IST / 9:00 AM EDT
Hyderabad, India, July 05, 2018
Dr. Reddy's Laboratories (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended June 30, 2018 on Thursday, July 26, 2018 after the Board Meeting.
| Event | Date and Time | Medium | ||
| Release of financial results | July 26 th , after the Board Meeting | Email, Media, Company website, Business wire | ||
| Earnings Call | July 26 th , 6:30 PM IST / 9:00 AM EDT | Hosted by the Company (Details below) | ||
| Playback of Earnings Call | After the earnings call till August 1 st | Details below | ||
| Transcript of the Earnings call | Will be available on the Company's website | URL available on Company's website, www.drreddys.com | ||
| Press meet presentation | Will be available on the Company's website | URL available on Company's website, www.drreddys.com |
Following the release, the management of
the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given
The play back will be available after the
earnings call, through August 1st, 2018. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and ID: 375#.
Conference Dial-In Numbers
| Primary Number: | +91 22 6280 1219 |
| Secondary Number: | +91 22 7115 8120 |
The numbers listed above are universally accessible from
all networks and all countries.
| Local Access Number: | Available all over India +91 70456 71221 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the
above numbers. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr Reddy's operates in markets across the globe. Our Major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information